Additional Studies. NEOTHERAPEUTICS reserves the right, subject to the approval and oversight of the Joint Development Committee, which approval will not be unreasonably withheld, to propose additional studies of Satraplatin at its own expense.
Appears in 3 contracts
Sources: Co Development and License Agreement (GPC Biotech Ag), Co Development and License Agreement (Neotherapeutics Inc), Co Development and License Agreement (Spectrum Pharmaceuticals Inc)